Craig-Hallum Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $45
Craig-Hallum analyst Robin Garner initiates coverage on Landos Biopharma (NASDAQ:LABP) with a Buy rating and announces Price Target of $45.
HC Wainwright & Co. Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $50
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Landos Biopharma (NASDAQ:LABP) with a Buy rating and announces Price Target of $50.
Landos Biopharma Announces FDA Clearance Of Its IND For LABP-104 For The Treatment Of Systemic Lupus Erythematosus
Landos Biopharma, Inc. (NASDAQ:LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases,
Landos Biopharma Announces Publication In Scientific Reports Of Novel Preclinical Findings Demonstrating Omilancor’s Therapeutic Potential In Models Of Psoriasis And Further Validating The LANCL2 Mechanism
Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases,
JonesTrading Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $39
JonesTrading analyst Prakhar Agrawal initiates coverage on Landos Biopharma (NASDAQ:LABP) with a Buy rating and announces Price Target of $39.
Landos Biopharma To Collaborate On A Phase 2 Study Of Omilancor In Crohn’s Disease With The Icahn School Of Medicine At Mount Sinai
Second Phase 2 trial of omilancor in Crohn’s disease (CD), expected to initiate in 2021
Awarded a $3 million NIH R01 grant from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases to fund
Raymond James Maintains Outperform on Landos Biopharma, Raises Price Target to $35
Raymond James analyst Steven Seedhouse maintains Landos Biopharma (NASDAQ:LABP) with a Outperform and raises the price target from $33 to $35.
Landos Biopharma Announces Outcome Of End-Of-Phase 2 Meeting With FDA For Omilancor In Mild-To-Moderate Active Ulcerative Colitis; Co. And FDA Agreed On Key Elements Necessary For Approval
Landos Biopharma, Inc. (NASDAQ:LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced Artificial Intelligence (A.I.) platform to discover and develop novel oral therapeutics for patients with